2. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998;98:734‚Äì741.
3. Montalescot G, Barragan P, Wittenberg O, et al; ADMIRAL Investigators. Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895‚Äì1903.
4. Morishima I, Sone T, Mokuno S, et al. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal coronary angioplasty. Am Heart J 1995;130:239‚Äì243.
5. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778‚Äì782.
6. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223‚Äì228.
7. Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202‚Äì1209.
8. Brener SJ, Ellis SG, Sapp SK, et al. Predictors of death and reinfarction at 30 days after primary angioplasty: The GUSTO IIb and RAPPORT trials. Am Heart J 2000;139:476‚Äì481.
9. Mehta RH, Harjai KJ, Cox D, et al. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Clinical and angiographic correlates and outcomes of suboptimal coronary flow in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1739‚Äì1746.
10. Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003;145:42‚Äì46.
11. Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol 2007;99:442‚Äì445.
12. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656‚Äì662.
13. Porto I, Ashar V, Mitchell AR. Pharmacological management of no reflow during percutaneous coronary intervention. Curr Vasc Pharmacol 2006;4:95‚Äì100.
14. Kelly RV, Crouch E, Krumnacher H, et al. Safety of adjunctive intracoronary thrombolytic therapy during complex percutaneous coronary intervention: Initial experience with intracoronary tenecteplase. Catheter Cardiovasc Interv 2005;66:327‚Äì332.
15. Nagai N, Demarsin E, Van Hoef B, et al. Recombinant human microplasmin: Production and potential therapeutic properties. J Thromb Haemost 2003;1:307‚Äì313.